文献速递心律失常血脂与心血管预防

达比加群酯与华法林预防中国非瓣膜性心房颤动患者卒中的比较:RE-LY 试验中国亚组分析

[Dabigatran versus warfarin for the prevention of stroke in Chinese patients with nonvalvular atrial fibrillation: Chinese subpopulation analysis of RE-LY].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2016-01-01

RE-LY 中国亚组纳入 13 个中心 541 例有卒中风险的非瓣膜性心房颤动患者,随机接受达比加群酯 110 mg 或 150 mg 每日两次(盲法)或调整剂量华法林(非盲法)。卒中年发生率在华法林组为 2.87%,达比加群酯 110 mg 组为 1.94%、150 mg 组为 1.10%;大出血年发生率华法林组为 1.43%,两个达比加群酯组均为 0.56%。作者认为由于样本量有限,该分析属描述性统计,结果提示达比加群酯对中国有卒中风险的心房颤动患者预防血栓栓塞有效且安全。

要点

  • 中国亚组卒中/体循环栓塞年发生率:华法林 2.87%,达比加群酯 110 mg 组 1.94%,150 mg 组 1.10%。
  • 大出血年发生率:华法林 1.43%,达比加群酯 110 mg 与 150 mg 组均为 0.56%。
  • 消化不良等胃肠道不良事件发生率:两个达比加群酯组均为 12.8%,华法林组为 5.6%。

核心结论

  • 作者认为,尽管因样本量有限本研究属描述性统计分析,该亚组分析提示达比加群酯与华法林一样,对中国有卒中风险的心房颤动患者预防血栓栓塞有效且安全。

研究设计与样本

  • RE-LY 为前瞻性、开放标签、随机、多中心研究;2006 年 3 月至 2009 年 3 月从中国 13 个医疗中心招募 541 例有卒中风险的心房颤动患者。
  • 患者随机接受盲法固定剂量达比加群酯 110 mg 或 150 mg 每日两次,或非盲法调整剂量华法林。
  • 主要疗效终点为卒中或体循环栓塞,主要安全终点为大出血。

主要发现

  • 卒中年发生率:达比加群酯 110 mg 组 1.94%(7 例),达比加群酯 150 mg 组 1.10%(4 例),华法林组 2.87%(10 例)。
  • 缺血性卒中年发生率:达比加群酯 110 mg 组 1.11%(4 例),150 mg 组 0.82%(3 例),华法林组 2.01%(7 例)。
  • 出血性卒中年发生率:达比加群酯 110 mg 组 0.28%(1 例),150 mg 组 0.27%(1 例),华法林组 0.57%(2 例)。
  • 全因死亡年发生率三组相近:达比加群酯 110 mg 组 3.33%(12 例),150 mg 组 2.19%(8 例),华法林组 2.58%(9 例)。
  • 大出血年发生率:两个达比加群酯组均为 0.56%(2 例),华法林组为 1.43%(5 例);消化不良等胃肠道不良事件发生率两个达比加群酯组均为 12.8%,华法林组为 5.6%。

临床怎么用

  • 作者认为,对中国有卒中风险的非瓣膜性心房颤动患者,达比加群酯与华法林一样可用于预防血栓栓塞且安全,但该结论基于样本量有限的描述性统计分析。

局限性

  • 作者指出本研究因样本量有限,本质上属描述性统计分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This analysis was performed to evaluate the efficacy in stroke prevention and safety of dabigatran in Chinese nonvalvular atrial fibrillation(NVAF) patients enrolled in RE-LY trial. Methods: RE-LY was an prospective, open-label, randomized, multicenter study. From March 2006 to March 2009, 541 atrial fibrillation patients at risk of stroke were recruited from 13 medical centers in China. Patients randomly received, in a blinded fashion, fixed doses of dabigatran-110 mg or 150 mg twice daily or, in an unblinded fashion, adjusted-dose warfarin. The primary efficacy endpoint was stroke or systemic embolism. The primary safety endpoint was major bleeding. Results: The incidence of stroke in the Chinese subpopulation was 1.94% per year(7 cases) in the group that received 110 mg of dabigatran (dabigatran 110) and 1.10% per year(4 cases) in the group that received 150 mg of dabigatran (dabigatran 150), as compared with 2.87% per year (10 cases) in warfarin group . Incidence of ischemic stroke was 1.11% per year(4 patients) in dabigatran 110 group, 0.82% per year(3 cases) in dabigatran 150 group and 2.01% per year(7 patients) in warfarin group. Incidence of hemorrhagic stroke was 0.28% per year(1 case) in dabigatran 110 group, 0.27% per year(1 case) in dabigatran 150 group and 0.57% per year(2 cases) in warfarin group. All-cause mortality was similar among the three treatment groups: 3.33% per year(12 cases) in dabigatran 110, 2.19% per year(8 cases) in dabigatran 150 and 2.58% per year(9 cases) in warfarin group. Incidence of major bleeding event was 0.56% per year(2 cases) in both dabigatran groups, as compared with 1.43% per year(5 cases) in warfarin group. Gastrointestinal disorders such as dyspepsia occurred in 12.8% patients of both dabigatran groups, and in 5.6% patients of warfarin group. Conclusions: Despite the descriptive statistical analysis in nature of present study due to the limited number of subjects, our subgroup analysis implies that like warfarin, dabigatran is efficacious and safe for thromboembolism prevention in Chinese patients with atrial fibrillation at risk of stroke. Clinical Trail Registry National Institutes of Health(http: //www.clinicaltrials.gov), CT00262600.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Gao X, Yang YM, Zhu J, et al. [Dabigatran versus warfarin for the prevention of stroke in Chinese patients with nonvalvular atrial fibrillation: Chinese subpopulation analysis of RE-LY]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016. PMID: 27903389. doi:10.3760/cma.j.issn.0253-3758.2016.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。